We determined urinary concentrations of α1-microglobulin and albumin in 155 patients with reflux nephropathy including 72 prepubertal (48 males and 24 females) and 83 postpubertal patients (43 males and 40 females) to elucidate the effect of age and gender in the progression of renal damage. Vesicoureteral reflux was resolved in all patients at least two years before enrollment into this study. Renal scarring was diagnosed with 99mtechnetium dimercaptosuccinic acid renal scan. More severe renal scarring was found predominantly in male compared to female patients. Urinary α1-microglobulin levels were significantly lower in postpubertal female patients (mean ± SD: 1.59 ± 1.02 mg/g creatinine) than in prepubertal males and females (3.32 ± 3.53 and 4.06 ± 4, respectively; p < 0.007 and p < 0.002, respectively), and in postpubertal males (3.69 ± 2.6; p < 0.002) regardless of severity of renal scarring. In the patients with severe unilateral renal scarring, urinary albumin levels were significantly higher in postpubertal males (81.9 ± 239.5) than in prepubertal males and postpubertal females (25.8 ± 63.1 and 13.8 ± 7.7, respectively; p < 0.05 and p < 0.05, respectively). Our results suggest that glomerular injury may develop during adolescence predominantly in male patients with severe renal scarring. In contrast, renal damage indicated by urinary α1-microglobulon level appears to be ameliorated in female postpubertal patients. This gender difference may be attributed to sex hormones.

Keywords:
Vesicoureteral reflux, Age, Gender, α1-Microglobulin, Albumin
1.
Bailey RR: Vesico-ureteric reflux and reflux nephropathy. Kidney Int 1993;42:S80–S85.
2.
Fivush BA, Jabs K, Neu AM, Sullivan EK, Feld L, Kohaut E, Fine R: Chronic renal insufficiency in children and adolescence: The 1996 annual report of NAPRTCS. Pediatr Nephrol 1998;12:328–337.
3.
Dillon MJ, Goonasekera CDA: Reflux nephropathy. J Am Soc Nephrol 1998;9:2377–2383.
4.
Zhang Y, Bailey RR: A long term follow up of adults with reflux nephropathy. Nz Med J 1995;108:142–144.
5.
Jacobson SH, Eklof O, Eriksson CG, Lins LE, Tidgren B, Winberg J: Development of hypertension and uraemia after pyelonephritis in childhood: 27 year follow up. Br Med J 1989;299:703–706.
6.
Hiraoka M, Hori C, Tsukahara H, Kasuga K, Ishihara Y, Sudo M: Congenital small kidneys with reflux as a common cause of nephropathy in boys. Kidney Int 1997;52:811–816.
7.
Assael BM, Guez S, Marra G, Secco M, Manzoni G, Bosio M, Pelegatta A, Acerbi L, Delli’Agnola CA, Selvaggio G, Vegni M, Cecchetti V, Cucchi L: Congenital reflux nephropathy: A follow-up of 108 cases diagnosed perinatally. Br J Urol 1998;82:252–257.
8.
Risdon RA, Yeung CK, Ransley PG: Reflux nephropathy in children submitted to unilateral nephrectomy: A clinicopathological study. Clin Nephrol 1993;40:308–314.
9.
Konda R, Sakai K, Ota S, Takeda A, Orikasa S: Follow-up study of renal function in children with reflux nephropathy after resolution of vesicoureteral reflux. J Urol 1997;157:975–979.
10.
Matsuoka H, Oshima K, Sakamoto K, Taguchi T, Takebayashi S: Renal pathology in patients with reflux nephropathy. Eur Urol 1994;26:153–159.
11.
Gretz N, Zeier M, Geberth S, Strauch M, Ritz E: Is gender a determinant for evolution of renal failure? A study in autosomal dominant polycystic kidney disease. Am J Kidney Dis 1989;14:178–183.
12.
Coggins CH, Lewis JB, Caggiula AW, Castaldo LS, Klahr S, Wang SR: Difference between women and men with chronic renal disease. Nephrol Dial Transplant 1998;13:1430–1437.
13.
Hannedouche T, Chauveau P, Kalou F, Albouze G, Lacour B, Jungers P: Factors affecting progression in advanced chronic renal failure. Clin Nephrol 1993;39:312–320.
14.
Jungers P, Chauveau P, Descamps-Latscha B, Labrunie M, Giraud E, Man NK, Grunfeld JP, Jacobs C: Age- and gender-related incidence of chronic renal failure in a French urban area: A prospective epidemiologic study. Nephrol Dial Transplant 1996;11:1542–1546.
15.
Neugarten J, Acharya A, Silbiger SR: Effect of gender on the progression of nondiabetic renal disease: A meta-analysis. J Am Soc Nephrol 2000;11:319–329.
16.
Matsusaka T, Hymes J, Ichikawa I: Angiotensin in progressive renal diseases: Theory and practice. J Am Soc Nephrol 1996;7:2025–2043.
17.
Konda R, Orikasa S, Sakai K, Ota S, Kimura N: The distribution of renin containing cells in scarred kidneys. J Urol 1996;156:1450–1454.
18.
Miller JA, Anacta LA, Cattran DC: Impact of gender on the renal response to angiotensin II. Kidney Int 1999;55:278–285.
19.
Fukatsu A, Matsuo S, Yuzawa Y, Miyai H, Futenma A, Kato K: Expression of interleukin 6 and major histocompatibility complex molecules in tubular epithelial cells of diseased human kidneys. Lab Invest 1993;69:58–67.
20.
Wang J, Konda R, Sato H, Sakai K, Ito S, Orikasa S: Clinical significance of urinary interleukin-6 in children with reflux nephropathy. J Urol 2001;165:210–214.
21.
Girasole G, Jilka R.L, Passeri G, Boswell S, Boder G, Williams DC, Manolagas SC: 17β-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: A potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest 1992;89:883–891.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.